* Editor's note: there are two sections designated as § 17-2101.
As used in this chapter, the following terms have the following meanings:
Nightlife establishment. The term "nightlife establishment" means an establishment in the city that is open to the public for entertainment or leisure and serves alcohol or where alcohol is consumed on the premises. Such term includes, but is not limited to, bars, entertainment venues, clubs and restaurants.
Opioid antagonist. The term "opioid antagonist" means naloxone, narcan or any other medication approved by the New York state department of health and the federal food and drug administration that, when administered, negates or neutralizes in whole or in part the pharmacological effects of an opioid in the human body.
(L.L. 2022/092, 10/12/2022, eff. 2/9/2023)
The commissioner shall coordinate with the director of the office of nightlife to establish a program whereby an employee of a nightlife establishment may request an opioid antagonist from the department that is intended to be administered to individuals on the premises of such establishment. Such program shall be operated in compliance with existing federal, state and local laws, rules and regulations relating to the distribution of an opioid antagonist.
(L.L. 2022/092, 10/12/2022, eff. 2/9/2023)
a. An employee of a nightlife establishment may request up to 5 kits of an opioid antagonist at one time.
b. To request an opioid antagonist, such employee shall provide the following information to the department:
1. Name, mailing address, zip code and contact information of such employee or establishment;
2. Number and type of opioid antagonist kits requested; and
3. Any other information the department determines is required to provide an opioid antagonist to such employee.
c. The department shall not charge a fee for receiving an opioid antagonist.
d. Such employee shall comply with all applicable federal, state and local laws, rules and regulations, including the requirements of this chapter.
(L.L. 2022/092, 10/12/2022, eff. 2/9/2023)
Loading...